At the ESMO 2018 Conference that was recently concluded, there was a report of the clinical experience of 100 men with metastatic castrate resistant prostate cancer (mCRPC) who were consecutively treated with Lu-177 PSMA-I&T Radioligand Therapy.
Apalutamide (Erleada) extends time to the development of first metastatic development and it does not degrade the quality of life.
Why you should take Provenge (sipuleucel-T) simply using evidence based logic.
The FDA has been asked to expand Zytiga's label to allow its use to treat men with earlier stages of metastatic prostate cancer.
On the horizon, a new Zytiga formulation. It's smaller and more active than the current Zytiga. It will be much easier to swallow.